MedTrace Logo

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

NCT00003603 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2013-09-20

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Steroids, such as dexamethasone or prednisolone, may help relieve some of the side effects of chemotherapy. It is not yet known which regimen of chemotherapy plus steroid therapy is more effective in treating patients with multiple myeloma.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of chemotherapy plus steroid therapy in treating patients with multiple myeloma that has recurred for the first time.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

cyclophosphamide

DRUG

dexamethasone

DRUG

idarubicin

DRUG

lomustine

DRUG

melphalan

DRUG

prednisolone

Sponsors & Collaborators

  • Riverside Haematology Group

    lead OTHER

Principal Investigators

  • Diana Samson, MD · Hammersmith Hospitals NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003603 on ClinicalTrials.gov